Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. It is the only North American company to offer biosimilars on market in Europe and Australia. Through its products, Hospira helps improve the safety, cost and productivity of patient care. Headquartered north of Chicago in Lake Forest, Ill., Hospira has approximately 19,000 employees worldwide and generated approximately $4.5 billion in net sales in 2014. Learn more >
PROPOSED MERGER WITH PFIZER INC.View Pfizer Inc. and Hospira, Inc. February 5, 2015 Press Release View Hospira’s Definitive Proxy Statement for the May 13, 2015 Special Meeting of Stockholders
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.